UBS maintains a 'Neutral' on PharMerica (PMC); Q1 Preview; Is There A Hangover From OCR’s Hostile Takeover Attempt?
Tweet
Share
E-mailGet Alerts PMC Hot Sheet
Price: $29.25 --0%
Rating Summary:
3 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 9
Rating Summary:
3 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 9
Join SI Premium – FREE
UBS maintains a 'Neutral' on PharMerica (NYSE: PMC) price target lowered from $15 to $13.
Analyst, Steven Valiquette, said, "We are projecting 1Q12 EPS of $0.29 for PharMerica, which is up +41% from $0.21 reported in 1Q2011, and is $0.01 above Street consensus. Like many of the companies in the drug distribution pipeline, PharMerica stands to benefit from the 1H12 launches of Lexapro, Seroquel, and Geodon which have fairly strong levels of distribution within the Long-term Care (LTC) channel."
"While shares of PMC trade at a discount to Omnicare (NYSE: OCR), we believe this discounted valuation is warranted given some of the lingering concerns for PMC’s near-term EPS growth prospects after being left at the altar by OCR courtesy of the FTC. We will obviously learn more over the next few quarters to what extent (if any) the PMC franchise was thwarted by this process."
For an analyst ratings summary and ratings history on PharMerica click here. For more ratings news on PharMerica click here.
Shares of PharMerica closed at $11.87 yesterday.
Analyst, Steven Valiquette, said, "We are projecting 1Q12 EPS of $0.29 for PharMerica, which is up +41% from $0.21 reported in 1Q2011, and is $0.01 above Street consensus. Like many of the companies in the drug distribution pipeline, PharMerica stands to benefit from the 1H12 launches of Lexapro, Seroquel, and Geodon which have fairly strong levels of distribution within the Long-term Care (LTC) channel."
"While shares of PMC trade at a discount to Omnicare (NYSE: OCR), we believe this discounted valuation is warranted given some of the lingering concerns for PMC’s near-term EPS growth prospects after being left at the altar by OCR courtesy of the FTC. We will obviously learn more over the next few quarters to what extent (if any) the PMC franchise was thwarted by this process."
For an analyst ratings summary and ratings history on PharMerica click here. For more ratings news on PharMerica click here.
Shares of PharMerica closed at $11.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Berenberg Upgrades Accelleron Industries AG (ACLN:SW) to Buy
- ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)
- RBC Capital Upgrades CAE Inc. (CAE:CN) (CAE) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT Change, Mergers and AcquisitionsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
